Mission Bio Status
The company raised $30 million of Series B venture funding from Agilent Technologies, Cota Capital and Mayfield Fund on December 13, 2018, putting the company's pre-money valuation at $40 million. Mighty Capital, LabCorp Ventures and LAM Research Capital also participated in the round. The company intends to use the funding to scale its unique single-cell DNA technology, the Tapestri® Platform, by expanding the market for blood cancer research, while at the same time broadening its scope to CRISPR applications and extending into global markets.
Leave a Reply ·
You must be logged in to post a comment.